A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Status:
Not yet recruiting
Trial end date:
2026-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition
to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the
composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).